Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration
about
Iron chelators for acute strokeIron chelators for acute strokeTowards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesOxidative Stress in Intracerebral Hemorrhage: Sources, Mechanisms, and Therapeutic TargetsIntracerebral hemorrhage in mouse models: therapeutic interventions and functional recoveryToxic role of prostaglandin E2 receptor EP1 after intracerebral hemorrhage in miceIron toxicity in mice with collagenase-induced intracerebral hemorrhageEfficacy of deferoxamine in animal models of intracerebral hemorrhage: a systematic review and stratified meta-analysisLocal injection of deferoxamine improves neovascularization in ischemic diabetic random flap by increasing HIF-1α and VEGF expressionIron regulatory protein-2 knockout increases perihematomal ferritin expression and cell viability after intracerebral hemorrhage.Deferoxamine attenuates acute hydrocephalus after traumatic brain injury in rats.Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage.1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-κB/RelA acetylation at Lys310Role of iron in brain injury after intraventricular hemorrhage.Brain injury after intracerebral hemorrhage in spontaneously hypertensive rats.The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage.Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhageMinocycline-induced attenuation of iron overload and brain injury after experimental intracerebral hemorrhageIron-induced necrotic brain cell death in rats with different aerobic capacity.Treatment targets in intracerebral hemorrhage.A critical appraisal of experimental intracerebral hemorrhage research.Curcumin attenuates brain edema in mice with intracerebral hemorrhage through inhibition of AQP4 and AQP9 expression.Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?Iron enhances the neurotoxicity of amyloid β.Deferoxamine reduces intracerebral hemorrhage-induced white matter damage in aged rats.Ischemic preconditioning attenuates brain edema after experimental intracerebral hemorrhage.Role of iron in brain lipocalin 2 upregulation after intracerebral hemorrhage in rats.Heme oxygenase-1-mediated neuroprotection in subarachnoid hemorrhage via intracerebroventricular deferoxamine.Deferoxamine reduces neuronal death and hematoma lysis after intracerebral hemorrhage in aged rats.Ferric iron chelation lowers brain iron levels after intracerebral hemorrhage in rats but does not improve outcome.Intracerebral haemorrhage: mechanisms of injury and therapeutic targets.New avenues for treatment of intracranial hemorrhage.Progress in translational research on intracerebral hemorrhage: is there an end in sight?Thrombin-induced cerebral hemorrhage: role of protease-activated receptor-1.Advances in neuroprotective strategies: potential therapies for intracerebral hemorrhage.Do current animal models of intracerebral hemorrhage mirror the human pathology?Neuroinflammation after intracerebral hemorrhage.Stages of the Inflammatory Response in Pathology and Tissue Repair after Intracerebral Hemorrhage.Modulators of microglial activation and polarization after intracerebral haemorrhage.Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis.
P2860
Q24200865-307E9600-5CE1-47DC-BD12-4CF927F8FDC4Q24235252-6489E2AE-DAE8-4B82-941E-2C1FBE6DD8BCQ24289511-E584883C-EBAD-48EC-9837-C6633641F236Q26769071-3380488F-5341-499F-A5A7-2A15B001978FQ26865843-AB605375-5C01-499C-86AD-E7EA3870CECAQ28257399-3525B7BC-18D8-4F42-96AF-F9481422ED99Q28299109-ACD51A09-68D9-4395-827D-870014D399CEQ28547438-1E7B6518-A00D-4C11-8654-D52C8D379084Q33807106-8603A809-90A6-4FD8-9526-BA68B0778A2FQ33990386-C722AAEB-1F9F-4B95-9BEB-08D31242D615Q34017056-42261566-D7C4-4ED7-83A2-25933E42A9EBQ34033129-E4B95A9D-F2B2-4C7C-99AA-21D7DAE01303Q34292783-E0F559B7-7439-4F17-A627-B091F80BEEE2Q34803059-61F29495-4792-4513-87EB-FD228FFFA562Q35022280-CA310AE0-340C-465A-AED1-690E2428B9B4Q35391420-9ED9E22A-87C3-4389-B4F5-E16971539460Q35449198-19B6C6F3-5D8D-40D4-BDE1-5B3C3479097EQ35581074-55C04462-0F01-4FF8-A5DB-294630FD4751Q35587322-2AB5AB5C-8567-40F1-BE73-122E73F5CF35Q35648063-4B8F2CA4-1AF3-4F63-B196-1433991B3847Q35866886-FB25B5F9-EEC6-4820-A52B-E44184185545Q36044826-E9E6C2BC-F207-47D7-8C3E-7CDA2EDC0D00Q36079321-F32E3988-75C5-4EF2-9730-35C6EB45F761Q36106030-63451D16-C0D6-4260-ABED-520D8E33761FQ36343190-5AD3493E-3A2F-4546-8C5F-0DD07318EF78Q36399779-5B499B5B-985E-42C9-AEE2-C50C72A42A5FQ36707641-9600844B-EB83-44EF-9455-F6C88A6AA396Q37251286-AFFAA79B-4B0D-4A5E-B72D-D67F358BE48DQ37262595-22310DB6-95DB-4DD6-95A8-D28E3EC7940AQ37360337-F8CB8B43-165B-416C-9E18-D2A60FBE8BDCQ37448194-4D505DFC-BB01-4741-A2D3-852714AE7325Q37598901-36CB576E-DC6C-4B0B-9621-9F9C57125262Q37652936-DEAEEBD4-44C9-4FF0-B075-0F9A2E591A0CQ37655796-5EF276F4-A5AC-4FB4-AFFA-20A6681B67CAQ37823080-BBD55313-BCA2-4FE4-921A-8EF478F8579DQ38170028-9EE9C5E7-5FAD-4A5A-BCC4-A37624CC486DQ38283522-16C114B3-D23B-4394-861D-7D90B8FCFB48Q38841916-4FDCB4AF-F3F0-4B3D-918A-7B91839B9B96Q39317715-38669F53-CB0D-4308-AB8D-8353EBBC3B66Q40312201-275B0019-A06E-4533-B4A2-80BB109877F2
P2860
Deferoxamine treatment for intracerebral hemorrhage in aged rats: therapeutic time window and optimal duration
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Deferoxamine treatment for int ...... me window and optimal duration
@ast
Deferoxamine treatment for int ...... me window and optimal duration
@en
type
label
Deferoxamine treatment for int ...... me window and optimal duration
@ast
Deferoxamine treatment for int ...... me window and optimal duration
@en
prefLabel
Deferoxamine treatment for int ...... me window and optimal duration
@ast
Deferoxamine treatment for int ...... me window and optimal duration
@en
P2093
P2860
P1433
P1476
Deferoxamine treatment for int ...... me window and optimal duration
@en
P2093
Lewis B Morgenstern
Masanobu Okauchi
Richard F Keep
Timothy Schallert
P2860
P304
P356
10.1161/STROKEAHA.109.569830
P407
P577
2009-12-31T00:00:00Z